Carisma Begin Period Cash Flow from 2010 to 2024
| CARM Stock | 0.69 0.09 11.54% |
Begin Period Cash Flow | First Reported 2012-12-31 | Previous Quarter 56.5 M | Current Value 62.8 M | Quarterly Volatility 34.4 M |
Check Carisma Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carisma Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3 M, Interest Expense of 2 M or Selling General Administrative of 31 M, as well as many indicators such as Price To Sales Ratio of 6.25, Dividend Yield of 0.0 or PTB Ratio of 3.89. Carisma financial statements analysis is a perfect complement when working with Carisma Therapeutics Valuation or Volatility modules.
Carisma | Begin Period Cash Flow |
Latest Carisma Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Carisma Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Carisma Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Carisma Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Carisma Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 32,279,437 | |
| Geometric Mean | 14,685,149 | |
| Coefficient Of Variation | 126.41 | |
| Mean Deviation | 26,524,124 | |
| Median | 24,194,000 | |
| Standard Deviation | 40,804,618 | |
| Sample Variance | 1665T | |
| Range | 161.9M | |
| R-Value | 0.52 | |
| Mean Square Error | 1301.8T | |
| R-Squared | 0.27 | |
| Significance | 0.05 | |
| Slope | 4,775,900 | |
| Total Sum of Squares | 23310.2T |
Carisma Begin Period Cash Flow History
About Carisma Therapeutics Financial Statements
Carisma Therapeutics investors utilize fundamental indicators, such as Begin Period Cash Flow, to predict how Carisma Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 24.2 M | 37.6 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Carisma Therapeutics Correlation against competitors. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.